Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Business Wire•10/11/2026•08:00 ET
0
Key Highlights
- ➤ALSTARS enrollment completed with 137 participants, versus 120 planned
- ➤Topline ALSTARS data expected in early Q2 2027
- ➤Cash and equivalents $35.8 million, funding operations past topline readout into H2 2027
- ➤Q3 collaboration revenue $0.2 million, down from $3.6 million year over year
- ➤Q3 net loss $10.6 million, compared with $2.1 million year over year
Expert Statements
Arun Swaminathan, Chief Executive Officer of Coya Therapeutics
“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS”
Arun Swaminathan, Chief Executive Officer of Coya Therapeutics
“With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”
Fred Grossman, President and Chief Medical Officer of Coya Therapeutics
“Completion of the ALSTARS trial is an important milestone as we move forward in our quest for providing a potential therapy for this lethal disease”
Fred Grossman, President and Chief Medical Officer of Coya Therapeutics
“The addition of the open-label extension provides participants the opportunity to continue on COYA 302 while we continue to collect important data.”
Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.
Get started
Create a free account to read the full story.